Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL15054707 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL33987 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11039957 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL16685075 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL22721 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL23062790 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL12542739 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20535729 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20607531 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3692334 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121691-B2 | Antimicrobial caps for medical connectors | BECTON, DICKINSON AND COMPANY (US) | 2024-10-22 | — | — | US | claimed |
| WO-2023091145-A1 | IMPROVED BIOSYNTHETIC WOUND AND BURN DRESSING WITH SILVER-BASED BROAD ANTIMICROBIAL ACTIVITY | WOODROOF E AUBREY (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4121236-A1 | COMPOSITIONS AND METHODS FOR PARTICLE THREE-DIMENSIONAL PRINTING | Holo, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| EP-3466481-B1 | ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS | BECTON DICKINSON CO (US) | 2022-11-02 | — | — | EP | claimed |
| US-20220339424-A1 | ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS | BECTON, DICKINSON AND COMPANY | 2022-10-27 | — | — | US | claimed |
| US-11357965-B2 | Antimicrobial caps for medical connectors | BECTON, DICKINSON AND COMPANY (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022046930-A1 | ANTIVIRAL AND ANTIMICROBIAL PROTECTIVE FILMS WITH MICROSTRUCTURE DETERRENTS | LUMENCO, LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220063178-A1 | ANTIVIRAL AND ANTIMICROBIAL PROTECTIVE FILMS WITH MICROSTRUCTURE DETERRENTS COMBINED WITH THERMALLY ELASTOMERIC AND EMBEDDED CHEMICAL ANTI-BACTERIAL OR ANTI-VIRAL AGENTS | MICROBEPROOF, LLC | 2022-03-03 | — | — | US | claimed |
| CN-111150931-B | Antibacterial cap for medical connector | 贝克顿·迪金森公司 | 2021-10-19 | — | — | CN | claimed |
| WO-2021188638-A1 | COMPOSITIONS AND METHODS FOR PARTICLE THREE-DIMENSIONAL PRINTING | HOLO, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-9060511-B2 | Compositions of dibromomalanomide and their use as biocides | ROHM AND HAAS COMPANY (US) | 2015-06-23 | — | — | US | claimed |
| CN-103068229-B | Dibromomalonamide compositions and their use as biocides | DOW GLOBAL TECHNOLOGIES INC | 2015-05-20 | — | — | CN | claimed |
| EP-2582238-B1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-06-06 | — | — | US | claimed |
| EP-2582238-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | Dow Global Technologies LLC (US) | 2013-04-24 | — | — | EP | claimed |
| CN-103068229-A | Dibromomalonamide compositions and their use as biocides | DOW GLOBAL TECHNOLOGIES LLC | 2013-04-24 | — | — | CN | claimed |
| US-20120225126-A1 | SOLID STATE SYNTHESIS METHOD OF SILVER NANOPARTICLES, AND SILVER NANOPARTICLES SYNTHESIZED THEREBY | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-09-06 | — | — | US | claimed |
| WO-2012021340-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-16 | — | — | WO | claimed |
| WO-2006056570-A1 | METHOD FOR PRODUCING LIVE FOOD WATER ORGANISMS IN THE PRESENCE OF AN ANTIBACTERIAL | INVE TECHNOLOGIES NV (BE) | 2006-06-01 | — | — | WO | claimed |
| EP-1658776-A1 | Method for producing live food water organisms in the presence of an antibacterial | Inve Technologies N.V. (BE) | 2006-05-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DDT, BCHE, MGAM | MEN1 2489/4885ALDH1A1 1719/4885HMGCR 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.